Tuesday, September 8, 2026

Sources: 1 podcast report analyzed

Coverage: Bloomberg Stock Movers

Executive Summary: Only one of the two scheduled episodes yielded usable transcript content today — the FT News Briefing transcript file contained a mis-scraped, unrelated article rather than the episode's actual content, so no cross-source comparison is possible for September 8. Today's coverage rests entirely on Bloomberg Stock Movers, which described a mixed session: healthcare stress from Novartis and Boston Scientific against relative strength in semiconductors via Intel.

Mentioned in: Bloomberg Stock Movers

Novartis shares plunged the most since 2020 after a muscle-wasting disease treatment failed to meet its primary trial endpoint — the third clinical trial setback in a single week, following a failed heart medication study and another halted trial. The weakness spilled into the broader biotech sector, dragging down Amgen, which is running its own late-stage heart disease drug trial.

Separately, Boston Scientific disclosed that a cybersecurity incident first identified on August 25 will likely cause it to miss previously issued Q3 and full-year sales and earnings guidance, after the attack disrupted order processing, shipping, and manufacturing systems. The hosts framed this as part of a broader pattern of recent cyberattacks hitting top MedTech companies.

Read more:

Bloomberg Stock Movers › Key Stories & Changes › 1

Mentioned in: Bloomberg Stock Movers

Intel shares outperformed in pre-market trading on reports the company plans to raise CPU prices by 10% starting in early October, sourced to Taiwan's Digitimes citing unnamed sources. The report describes this as continuing a price-raising pattern that began at the end of 2025, attributed to supply chain costs and strong demand; Intel had not confirmed the report as of the episode's airing.

Read more:

Bloomberg Stock Movers › Key Stories & Changes › 3

Intel — Shares outperforming pre-market on reports of a planned 10% CPU price hike in October — Bloomberg Stock Movers

Novartis — Shares plunged the most since 2020 after a third failed clinical trial in one week — Bloomberg Stock Movers

Amgen / Biotech sector — Shares dragged down in sympathy with Novartis's pipeline failures — Bloomberg Stock Movers

Boston Scientific — Guidance likely to miss Q3 and full-year targets due to a cyberattack disrupting operations — Bloomberg Stock Movers

Novartis — Miss — Muscle-wasting disease drug failed primary trial endpoint; shares down most since 2020 — Bloomberg Stock Movers

Boston Scientific — Miss — Likely to miss Q3 and full-year net sales growth and adjusted earnings guidance — Bloomberg Stock Movers

Novartis pipeline follow-through — Watch for further disclosures after three trial failures in one week; Bloomberg Stock Movers flagged ongoing analyst concern about the company's growth profile.

Boston Scientific recovery progress — Company said it anticipates recovering some portion of impacted revenue as operations ramp back up from the cyberattack; watch for updates on the timeline.

Intel price hike confirmation — The reported 10% CPU price increase is based on a single outlet citing unnamed sources; watch for Intel's own confirmation ahead of the reported early-October implementation.

MedTech cybersecurity exposure — Bloomberg Stock Movers noted Boston Scientific's incident is part of a broader pattern of attacks on top MedTech companies; watch for further disclosures across the sector.

Novartis pipeline attrition (1 source) — Three separate clinical trial failures in one week raise doubts about near-term growth, per Bloomberg Stock Movers.

Cross-company biotech contagion (1 source) — Amgen and other biotech names fell in sympathy with Novartis despite no company-specific news, per Bloomberg Stock Movers.

Boston Scientific guidance miss (1 source) — The company itself says it is unlikely to hit previously provided Q3 and full-year targets, per Bloomberg Stock Movers.

Sector-wide MedTech cyber exposure (1 source) — Bloomberg Stock Movers noted this is one of several recent attacks on top MedTech companies.

Unconfirmed Intel price-hike sourcing (1 source) — The reported 10% CPU price increase rests on a single publication citing unnamed sources, per Bloomberg Stock Movers.

Bloomberg Stock Movers — Mixed — Framed the session as a "good news, bad news morning" — healthcare pressure from Novartis and Boston Scientific offset by Intel strength.